Table 4 Summary of VEGF Trials
From: Therapy for metastatic melanoma: the past, present, and future
Trial | Patients | RR% (CR/PR) | PFS (months) | OS (months) | Number (patients) | Summary |
|---|---|---|---|---|---|---|
Single Arm Phase 2 Perez et al. [61] | Carboplatin plus paclitaxel and bevacizumab in unresectable metastatic melanoma | 17 | 6 | 12 | 53 | Carboplatin plus paclitaxel and bevacizumab was well tolerated and clinically beneficial |
Randomized Phase 2 Kim et al. [62] | Carboplatin plus paclitaxel and bevacizumab versus Carboplatin plus paclitaxel in untreated metastatic melanoma | 25.5 versus 16.4 | 5.6 versus 4.2 | 12.3 versus 8.6 | 214 | Carboplatin plus paclitaxel and bevacizumab demonstrated statistically significant improvement in OS |
Single Arm Phase 2 Kottschade et al. [63] | Carboplatin plus nab-paclitaxel in chemotherapy naïve(CN) and previously treated (PT) metastatic melanoma | 25.6 (CN) 8.8 (PT) | 4.5 (CN) 4.1 (PT) | 11.1 (CN) 10.1 (PT) | 41 (CN) 35 (PT) | Carboplatin plus nab-paclitaxel has clinical activity in chemotherapy naïve patients |
Single Arm Phase 2 Fruehauf et al. [64] | Axitiniba in metastatic melanoma after maximum on one prior therapy | 18.8% | 3.9 | 6.6 | 32 | Axitinib demonstrated clinical activity in metastatic melanoma. |